⚠ RecallRadar📷 ScanGuidesOfficial U.S. recall notices, restated plainly

Bristol-Myers Squibb Company: Opdualag (nivolumab and relatlimab-rmbw) injection, 240 mg and 80 mg/20 mL (12mg and 4mg/mL),Single Dose Vial, RX Only, Bristol-Myers Squibb

DrugsSource: FDA (drug) · Date: 2025-10-29

Read the official notice at FDA (drug) →

Share on XFacebookRedditEmail

Guides: Which agency handles which recall (FDA vs USDA vs CPSC vs NHTSA)

The text below is copied from the official FDA (drug) record. If anything differs, the official notice is correct.

Company / brand
Bristol-Myers Squibb Company
Product
Opdualag (nivolumab and relatlimab-rmbw) injection, 240 mg and 80 mg/20 mL (12mg and 4mg/mL),Single Dose Vial, RX Only, Bristol-Myers Squibb Company, Princeton, NJ 08543, NDC 0003-7125-11
Reason / hazard
Lack of Assurance of Sterility.
Classification
Class II
Status
Ongoing
Distribution / sold at
Nationwide in the USA
Recall initiated
2025-10-21
Code info
Lot: 033A23B, Expiry: 4/30/2026
Product quantity
12,778 total vials
Voluntary mandated
Voluntary: Firm initiated
City
New Brunswick
State
NJ
Country
United States
Event id
97839
Free daily digest + "My products" watchlist

Get the daily digest, and tell us what to watch. Everything is optional except your email.

Free allergen alerts:

Categories:

Privacy: we store only what you enter here, use it only to send recall alerts you asked for, never sell or share it, and you can unsubscribe anytime. Double opt-in: we will email you a confirmation link before sending anything; alerts start only after you confirm. Every email has unsubscribe and manage-watchlist links.